ANA Highlights Neurogenetics
A bite-size learning module series designed to close the knowledge gap about the current state of neurogenetics and the applications of genetic testing.
The ANA Highlights Neurogenetics program is chaired by Dr. M. Elizabeth Ross, Nathan Cummings Professor and Head, Laboratory of Neurogenetics and Development, Director, Center for Neurogenetics at Weill Cornell Medicine. The ANA Highlights bite-size learning program is chaired by Michelle C. Johansen, MD, PhD, Assistant Professor of Neurology, Cerebrovascular Division at the Johns Hopkins Hospital.
The ANA received a grant from Illumina in support of this activity.
This program is comprised of four chapters in the following topics and includes short (~15 minutes), pre-recorded videos. Following this activity, the ANA expects learners to be more confident in their ability to:
- Understand the different types of neurogenetic testing available today, and prospects for future developments
- Advise patients knowledgeably about the utility and advisability of genetic testing
- Communicate and collaborate more effectively with genetic counselors
- Recognize the legal and ethical issues involved with neurogenetic testing
- Improve patient care through the above-listed capabilities
Chapter 1. Introduction to Genetics: A primer for the practicing clinician: importance of family history and phenotype to accurate genetic diagnosis, e.g., when to order microarrays, disease gene panels, vs. whole exome vs. whole genome sequencing, use of specialized tests (i.e. suspected mosaicism, nucleotide repeat disorders), and pedigree analysis. Dr. Andrea Gropman, Chief of Neurogenetics and Neurodevelopmental Pediatrics and Attending Neurologist at Children’s National is the lead for this module.
Chapter 2. Emerging Issues in Neurogenetics: An overview of genetic testing research, variants of uncertain significance, role of somatic mosaicism in neurological diseases, the role of big data in tackling brain disorders of children and adults, pharmacogenomics and importance of genetic diversity in research toward clinical utility in neurology. Dr. M. Elizabeth Ross, Nathan Cummings Professor and Head, Laboratory of Neurogenetics and Development, Director, Center for Neurogenetics at Weill Cornell Medicine is the lead for this module.
Chapter 3. Clinical Utility of Neurogenetics: A journey from testing to prognosis to treatment/prevention to advocacy, testing children vs adults, clinical trials, why test, how to find trials, and a review of what treatments are available. Dr. Jennifer L Orthmann-Murphy, Assistant Professor of Neurology and Co-Director of Age Span Fellowship in MS/Neuroinflammatory Disorders at the University of Pennsylvania is the lead for this module.
Chapter 4. Ethical Considerations in Neurogenetics: An overview of ethical issues in a precision neurology world, medical-legal issues, pediatric populations, ethical challenges when dealing with specific conditions and diseases. Dr. Peter Todd, Bucky and Patti Harris Professor of Neurology at the University of Michigan is the lead for this module.
Following all of the modules is a quiz to allow you to claim ABPN Self Assessment CME credit. Please wait to complete the quiz/evaluation until after you have watched all videos for which you wish to claim CME. You will be able to claim up to 5.75 hours in the final evaluation - this is the value that will be displayed on your certificate. Your successful completion of this course will be automatically reported to the ABPN.
The planners and faculty for this activity do not have any relationships to disclose unless listed below. All relevant relationships with ACCME-defined ineligible companies were mitigated according to ACCME Standards prior to the start of the activity.
Gemma Carvill: Research grant with Stoke Therapeutics
Derek Narendra: Spark Therapeutics. I anticipate that my lab may receive research funding as part of a research collaboration prior to my presentation, but has not received this funding yet.
Daniel Geschwind: Biogen-honoraria for consulting, F.Hoffman-La Roche Ltd.-funding
- 5.75 AMA PRA Category 1 Credit™
- 5.75 Participation
- 5.75 ABPN Self Assessment Credit
The American Neurological Association is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The American Neurological Association designates this Enduring material for a maximum of 5.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The American Board of Psychiatry and Neurology has reviewed the ANA Highlights Neurogenetics and has approved this activity as part of a comprehensive Self-Assessment activity, which is mandated by the ABMS as a necessary component of Continuing Certification.
- 5.75 AMA PRA Category 1 Credit™The American Neurological Association is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. The American Neurological Association designates this Enduring material for a maximum of 5.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
- 5.75 Participation